[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371715-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371715-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","chk1-inhibition-increases-the-therapeutic-response-to-radiotherapy-via-antitumor-immunity-in-arid1a-deficient-colorectal-cancer","CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer","","Colorectal cancer (CRC) remains difficult to treat due to an immunosuppressive tumor microenvironment that restricts the effectiveness of immune checkpoint blockers. ARID1A deficiency is frequently found in CRC and is linked to enhanced mutation burden and immune-cell infiltration, suggesting stronger potential for immunotherapy. This study shows that ARID1A regulates CHK1 protein stability through DDB1-mediated ubiquitination, leading to CHK1 upregulation and cytosolic ssDNA accumulation. Inhibiting the ATR/CHK1 axis activates STING-mediated DNA sensing and increases intrinsic innate immunity, thereby enhancing radiotherapy and ICB therapeutic outcomes in ARID1A-deficient tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/chk1-inhibition-increases-the-therapeutic-response-to-radiotherapy-via-antitumor-immunity-in-arid1a-deficient-colorectal-cancer/371715/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/chk1-inhibition-increases-the-therapeutic-response-to-radiotherapy-via-antitumor-immunity-in-arid1a-deficient-colorectal-cancer/371715.png","ImageObject",300,407,{"name":42,"@type":43},"Stanley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are immune checkpoint blockers often less effective in colorectal cancer?","Question",{"text":63,"@type":64},"Colorectal cancer commonly develops an immunosuppressive tumor microenvironment, which limits the therapeutic efficacy of immune checkpoint blockers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What effect does ARID1A deficiency have on CHK1 and DNA sensing?",{"text":68,"@type":64},"ARID1A deficiency results in CHK1 upregulation and cytosolic single-strand DNA accumulation, which can engage DNA-sensing pathways.",{"name":70,"@type":61,"acceptedAnswer":71},"How does ATR/CHK1 axis targeting improve radiotherapy and ICB responses?",{"text":72,"@type":64},"Targeting the ATR/CHK1 axis triggers cancer cell-intrinsic innate immunity via the STING-mediated DNA-sensing pathway, enhancing radiotherapy and ICB therapeutic efficacy in ARID1A-deficient tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371715,1790219000,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nCHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deﬁcient colorectal cancer  \nJhen-Yu Chen1,2, Tao-Wei Ke3,4, Shu-Fen Chiang5, Wei-Ze Hong6, Hsin-Yu Chang6,7, Ji-An Liang8,9, Yuan-Yao Tsai3,10, Chi-Hsien Huang8,10, William Tzu-Liang Chen3,11,12, K. S. Clifford Chao 6,8,9 and Kevin Chih-Yang Huang 1,2,13 ✉  \n© The Author(s) 2025  \n|  |  |  |\n| --- | --- | --- |\n|  | Colorectal cancer (CRC) ranks among the most commonly diagnosed cancers globally and is characterized by high mortality ratesand signiﬁcant intertumoral heterogeneity driven by somatic mutations and an immunosuppressive tumor microenvironment (TME) . Despite the success of immune checkpoint blockers (ICBs) in various malignancies, the immunosuppressive TME limits their therapeutic efﬁcacy in the majority of CRC patients. Therefore, strategies to unleash antitumor immunity are imperative to increase the therapeutic outcomes of these patients. ARID1A mutation is frequently observed in cancers and is known to be associated with tumor activity and poor prognosis, such as colorectal cancer. Additionally, ARID1A deﬁciency is associated with a reduced mismatch repair capacity, increased cancer mutability, and increased inﬁltration of immune cells, thus potentiating the efﬁcacy of ICBs. In this study, we revealed that ARID1A regulates CHK1 protein stability through DDB1-mediated ubiquitination. ARID1A deﬁciency results in CHK1 upregulation and cytosolic single-strand DNA (ssDNA) accumulation. Targeting the ATR/CHK1 axis triggers cancer cell-intrinsic innate immunity via the STING-mediated DNA-sensing pathway, thereby enhancing the therapeutic efﬁcacy of radiotherapy (RT) and ICBs in ARID1A-deﬁcient tumors. Taken together, these ﬁndings suggest that targeting the CHK1 checkpoint may serve as a therapeutic strategy to remodel the TME and enhance the response to radiotherapy |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| and ICBs in ARID1A-deﬁcient CRC. |  |  |\n|  | Cell Death and Disease (2025)16:584; [https://doi.org/10.1038/s41419-025-07912-6](https://doi.org/10.1038/s41419-025-07912-6) |  |\n|  |  |  |\n\nINTRODUCTION  \nColorectal cancer (CRC) is one of the most prevalent cancers worldwide [1] . Due to the intertumoral heterogeneity caused by somatic mutations and the immunosuppressive tumor microenvironment (TME), a considerable proportion of CRC patients develop local recurrence and distant metastasis within 5 years after treatment. Despite the success of immune checkpoint blockers (ICBs) in various malignancies, the immunosuppressive TME also limits their therapeutic efﬁcacy in patients with CRC. Therefore, enhancing antitumor immunity to improve the therapeutic outcomes of patients with poorly immunologic CRCis necessary.  \nARID1A is a key component of the SWI/SNF chromatinremodeling complex, which is essential for DNA transcription, replication, and damage repair [2] . ARID1A gene mutations have been identiﬁed in approximately 10–15% of CRC cases [3, 4] .  \nThese ARID1A loss-of-function mutations resulted in reduced protein expression and impaired chromatin remodeling activity, and were strongly associated with tumor progression, distant metastases, and shorter overall survival [5–8] . Moreover, clinicopathological analyses revealed that ARID1A protein loss or reduced expression occurs in 77% of CRC patients [6, 9], and is associated with the advanced tumor-node-metastasis (TNM) stage, suggesting that ARID1A is a key tumor suppressor in CRC and its loss is strongly linked to CRC progression and metastasis. Given the high frequency of ARID1A loss or inactivation in cancer, the exploitation of anticancer therapeutics based on ARID1A status has been investigated. Recent studies have shown that targeting synthetic lethal partners of ARID1A uncovers selective vulnerabilities in ARID1A","cbCaipDIHyXGayEV","https://ap.wps.com/l/cbCaipDIHyXGayEV","pdf",4315438,14,"English","# Introduction\n## Background on colorectal cancer and immunosuppressive TME\n## Role of ARID1A mutations in CRC\n## Rationale for targeting ARID1A-related vulnerabilities and ATR/CHK1 axis","[{\"question\":\"Why are immune checkpoint blockers often less effective in colorectal cancer?\",\"answer\":\"Colorectal cancer commonly develops an immunosuppressive tumor microenvironment, which limits the therapeutic efficacy of immune checkpoint blockers.\"},{\"question\":\"What effect does ARID1A deficiency have on CHK1 and DNA sensing?\",\"answer\":\"ARID1A deficiency results in CHK1 upregulation and cytosolic single-strand DNA accumulation, which can engage DNA-sensing pathways.\"},{\"question\":\"How does ATR/CHK1 axis targeting improve radiotherapy and ICB responses?\",\"answer\":\"Targeting the ATR/CHK1 axis triggers cancer cell-intrinsic innate immunity via the STING-mediated DNA-sensing pathway, enhancing radiotherapy and ICB therapeutic efficacy in ARID1A-deficient tumors.\"}]","CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer | PDF",1790192688,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e468ae6136cbd52e8b89b4b381af195.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4e681f038b664ae30de6859d6e07050.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81457b75215525f4f20c07b361052dcc.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56bae1c865b2fe43e7987a29a4c57233.webp",980,1301]